The present invention relates to a novel thienopyrimidine derivative and a use thereof, and more particularly, to a novel thienopyrimidine derivative compound and a composition for preventing or treating cancer comprising the same. The compound of the present invention can be effectively used for treating cancer with high FLT3 inhibitory activity and safety. In particular, the compound of the present invention has excellent solubility in physiological salt solutions including water, and thus can be more effectively used for development of therapeutic agents for cancer.COPYRIGHT KIPO 2018
-
Paragraph 0121-0122
(2018/09/02)
COMPOUNDS HAVING AN ETHR INHIBITING ACTIVITY - USE OF SAID COMPOUNDS AS DRUGS - PHARMACEUTICAL COMPOSITION AND PRODUCT CONTAINING SAID COMPOUNDS
The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals : (II); (III); (IV), (V), (VI) (VII) and n= 1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.
-
Page/Page column 11; 12
(2013/05/21)
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors
Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic.
Methods of making 2,6-diaryl piperidine derivatives
Methods for preparing 2,6-diaryl piperidine derivatives are described. More particularly, 2,6-diaryl piperidines having formula 1-4 are prepared by cyclocondensation of an aryl or heteroaryl aldehyde with 1,3-acetonedicarboxylic acid.
-
(2008/06/13)
More Articles about upstream products of 25742-12-5